6/17
02:05 pm
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
6/11
11:27 am
gpcr
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data [Yahoo! Finance]
Medium
Report
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data [Yahoo! Finance]
6/7
04:05 pm
gpcr
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
Low
Report
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
6/7
11:08 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its price target raised by analysts at BMO Capital Markets from $83.00 to $100.00. They now have an "outperform" rating on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its price target raised by analysts at BMO Capital Markets from $83.00 to $100.00. They now have an "outperform" rating on the stock.
6/5
07:53 pm
gpcr
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
Low
Report
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
6/4
12:08 pm
gpcr
Qiming's Nisa Leung Made the 2024 Forbes Midas List
Low
Report
Qiming's Nisa Leung Made the 2024 Forbes Midas List
6/4
12:01 pm
gpcr
Qiming's Nisa Leung Made the 2024 Forbes Midas List
Low
Report
Qiming's Nisa Leung Made the 2024 Forbes Midas List
6/4
11:59 am
gpcr
Qiming's Nisa Leung Made the 2024 Forbes Midas List
Low
Report
Qiming's Nisa Leung Made the 2024 Forbes Midas List
6/3
04:12 pm
gpcr
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants [Yahoo! Finance]
6/3
04:09 pm
gpcr
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
Low
Report
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
6/3
11:06 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Medium
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
6/3
07:39 am
gpcr
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 [Yahoo! Finance]
Medium
Report
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 [Yahoo! Finance]
6/3
07:30 am
gpcr
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
High
Report
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
5/21
07:35 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $65.00 price target on the stock.
5/10
01:37 pm
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
Medium
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
5/9
04:24 pm
gpcr
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights [Yahoo! Finance]
Medium
Report
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights [Yahoo! Finance]
5/9
04:05 pm
gpcr
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
Medium
Report
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
5/3
01:34 pm
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
4/18
10:22 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
4/9
08:09 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $65.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $65.00 price target on the stock.